Trial reportMicrobial biotechnology2020
Efficacy of faecal microbiota transplantation in Crohn's disease: a new target treatment?
Trial report in Microbial biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01793831 (Efficacy and Safety of Standardized Fecal Microbiota Transplantation for Moderate to Severe Crohn&Apos;s Diseases), which is not on this map. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Standardized Fecal Microbiota Transplantation for Moderate to Severe Crohn&Apos;s Diseases
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Fecal microbiota transplantation for induction of remission in Crohn's disease: a systematic review and meta-analysis.International journal of colorectal disease · 2023Pooled it
- Encyclopedia of fecal microbiota transplantation: a review of effectiveness in the treatment of 85 diseases.Chinese medical journal · 2022Pooled it
- Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis.PloS one · 2020Pooled it
- Impact of cap-assisted colonoscopy during transendoscopic enteral tubing: A randomized controlled trial.World journal of gastroenterology · 2020Trial
- Efficacy of faecal microbiota transplantation in Crohn's disease: a new target treatment?Microbial biotechnology · 2020Trial
- Review
- Role and progression of bile acid metabolism in mediating Th17/Treg homeostasis in inflammatory bowel disease.iScience · 2026Review
- Development and validation of a model incorporating choroid plexus morphology from brain MRI to predict anti-TNF-α therapy outcomes in Crohn's disease.BMC gastroenterology · 2026Article
- From dysbiosis to precision medicine: targeting the microbial-metabolic axis in IBD management.Frontiers in cellular and infection microbiology · 2026Review
- Uncovering the role of microbiota and fecal microbiota transplantation in Crohn's disease: Current advances and future hurdles.World journal of methodology · 2025Review
- Article
- Baseline Fusobacterium Abundance Predicts Ustekinumab Response in Crohn's Disease: A Prospective Microbiome Cohort Study.Microbial biotechnology · 2025Article
- Gut Microbiota Modulation in IBD: From the Old Paradigm to Revolutionary Tools.International journal of molecular sciences · 2025Review
- Gut microbiota in Crohn's disease pathogenesis.World journal of gastroenterology · 2025Review
- Microbiome characterization of patients with Crohn disease and the use of fecal microbiota transplantation: A review.Medicine · 2025Review
- Fistula in Crohn's disease: classification, pathogenesis, and treatment options.Tissue barriers · 2025Review
- The Gut Microbiome Advances Precision Medicine and Diagnostics for Inflammatory Bowel Diseases.International journal of molecular sciences · 2024Review
- Article
- Comparison between washed microbiota transplantation and infliximab: Medical cost during long-term management in patients with inflammatory bowel disease.Journal of the Chinese Medical Association : JCMA · 2024Article
- Washed Microbiota Transplantation Improves the Sleep Quality in Patients with Inflammatory Bowel Disease.Nature and science of sleep · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficacy of faecal microbiota transplantation (FMT) in Crohn's disease (CD) remains unclear due to lack of data. This study aimed to assess the value of FMT in treating CD-related clinical targets. The use of FMT for CD as a registered trial (NCT01793831) was performed between October 2012 and December 2017. Seven therapeutic targets included abdominal pain, diarrhoea, hematochezia, fever, steroid-dependence, enterocutaneous fistula and active perianal fistula. Each target was recorded as 1 (yes) or 0 (no) during the long-term follow-up for each patient. The primary outcome was the rate of improvement in each therapeutic target. Overall, 174 patients completed the follow-up. The median follow-up duration was 43 (interquartile range, 28-59) months. The median score of the total targets was 2 (range, 1-4) before FMT, and it decreased significantly at 1, 3, 6, 12, 24 and 36 months after FMT (P < 0.001 respectively). At 1 month after FMT, 72.7% (101/139), 61.6% (90/146), 76% (19/25) and 70.6% (12/17) of patients achieved improvement in abdominal pain, diarrhoea, hematochezia and fever respectively. Furthermore, 50% (10/20) of steroid-dependent patients achieved steroid-free remission after FMT. The present findings indicate that it is important to understand the efficacy of FMT in CD as a targeted therapy, especially for abdominal pain, hematochezia, fever and diarrhoea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.